rs104894205
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The NM_003476.5(CSRP3):c.131T>C(p.Leu44Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000403 in 1,612,474 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/20 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_003476.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CSRP3 | NM_003476.5 | c.131T>C | p.Leu44Pro | missense_variant | 3/6 | ENST00000265968.9 | |
CSRP3 | NM_001369404.1 | c.113-1938T>C | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CSRP3 | ENST00000265968.9 | c.131T>C | p.Leu44Pro | missense_variant | 3/6 | 1 | NM_003476.5 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000525 AC: 8AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250870Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135586
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1460236Hom.: 0 Cov.: 32 AF XY: 0.0000358 AC XY: 26AN XY: 726408
GnomAD4 genome ? AF: 0.0000525 AC: 8AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.0000941 AC XY: 7AN XY: 74378
ClinVar
Submissions by phenotype
not provided Pathogenic:5Uncertain:1
Likely pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Feb 21, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 14, 2023 | Published functional studies suggest a damaging effect; however, it is not known whether these findings are biological or clinically relevant in vivo (Lange et al., 2016; Ehsan et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27532257, 30012424, 22429680, 18505755, 26183555, 25179549, 19115046, 27353086, 30048712, 35241752, 16352453, 25351510, 33662488, 32105245, 34495297, 31919335, 33035702, 12642359, 31513939) - |
Hypertrophic cardiomyopathy 12 Pathogenic:2
Likely pathogenic, no assertion criteria provided | clinical testing | Bioscientia Institut fuer Medizinische Diagnostik GmbH, Sonic Healthcare | Jun 25, 2019 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 18, 2003 | - - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | Dec 29, 2022 | ACMG categories: PS5,PM2,PP3,PP5 - |
Dilated cardiomyopathy 1M;C2677491:Hypertrophic cardiomyopathy 12 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 31, 2023 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 44 of the CSRP3 protein (p.Leu44Pro). This variant is present in population databases (rs104894205, gnomAD 0.003%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 12642359, 18505755; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8778). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CSRP3 function (PMID: 27353086, 30048712). For these reasons, this variant has been classified as Pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 14, 2012 | Variant classified as Uncertain Significance - Favor Pathogenic. The Leu44Pro va riant in CSRP3 has been identified in 1 individual with HCM, was absent from 100 0 control chromosomes and segregated with disease in 2 definitively and 1 possib ly affected relatives as well as one obligate carrier with unknown disease statu s (Geier 2003; Geier 2008). This variant was absent from two large and broad Eu ropean and African American populations screened by the NHLBI Exome Sequencing P roject (http://evs.gs.washington.edu/EVS; dbSNP rs104894205). The affected amino acid is highly conserved in evolution, suggesting that a change would impact th e protein. Other computational analyses (biochemical amino acid properties, Alig nGVGD, PolyPhen2, and SIFT) also suggest that the Leu44Pro variant may impact th e protein, though this information is not predictive enough to determine pathoge nicity. In summary, this data supports that the Leu44Pro variant may be pathoge nic but is insufficient to establish this with certainty. - |
Hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Human Genetics, University of Leuven | Oct 31, 2018 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 15, 2021 | The c.131T>C (p.L44P) alteration is located in exon 3 (coding exon 2) of the CSRP3 gene. This alteration results from a T to C substitution at nucleotide position 131, causing the leucine (L) at amino acid position 44 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at